(Approval lapsed) SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen 50 micrograms, powder and suspension for suspension for injection (GSK, NZ)
Section 19A approved medicine
(Approval lapsed) SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen 50 micrograms, powder and suspension for suspension for injection (GSK, NZ)
Section 19A approval holder
GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481
Phone
1800 033 109
Approved until
Status
Expired
Medicines in short supply/unavailable
SHINGRIX Recombinant Varicella Zoster Virus glycoprotein E antigen vaccine 50 micrograms powder vial and suspension vial for suspension for injection - ARTG 289257
Indication(s)
SHINGRIX is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in:
- adults 50 years of age or older;
- adults 18 years of age or older at increased risk of HZ.
Images
